Literature DB >> 15000307

[Urinary stones and urinary tract abnormalities. Is the stone composition independent of the anatomical abnormality?].

Michel Daudon1, Fabrice Cohen-Solal, Bernard Lacour, Paul Jungers.   

Abstract

INTRODUCTION: More than ten per cent of stones are associated with a urinary tract abnormality. To verify whether the malformation influences stone composition, we studied the composition of stones observed in fifteen urological abnormalities. MATERIAL AND
METHOD: This study is based on 1,461 stones associated with a clearly defined malformation analysed by infrared spectroscopy plus 402 bladder stones in men with benign prostatic hyperplasia.
RESULTS: In this series of 1,863 abnormalities, 732 (39.3%) involved the kidney, 561 (30.1%) involved the ureter and 570 (30.6%) involved the lower tract. Whewellite stones were predominant in all renal abnormalities with the exception of cysts, which were mainly associated with uric acid. The main differences concerned the second constituent: weddellite in horseshoe kidneys, carbapatite in Cacchi-Ricci disease and caliceal abnormalities. Struvite was uncommon (<10%). Whewellite was the main component in ureteric abnormalities except for megaureter and reflux in which carbapatite was predominant. Struvite was present in 10% to 30% of stones. Vesicourethral abnormalities were accompanied by calcium and magnesium phosphate stones (90% of cases), and struvite was present in 58% to 90% of cases. The exception to this general rule was bladder stones associated with benign prostatic hyperplasia, in which the main component was uric acid.
CONCLUSION: Significant differences in stone composition were observed as a function of anatomical abnormalities reflecting the fact that some abnormalities add infectious or metabolic risk factors to anatomical factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15000307

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  5 in total

1.  Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

Authors:  Matteo Bargagli; Nasser A Dhayat; Manuel Anderegg; Mariam Semmo; Uyen Huynh-Do; Bruno Vogt; Pietro Manuel Ferraro; Daniel G Fuster
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

Review 2.  Lithiasis in cystic kidney disease and malformations of the urinary tract.

Authors:  G Gambaro; A Fabris; D Puliatta; A Lupo
Journal:  Urol Res       Date:  2006-01-14

3.  Bone disease in medullary sponge kidney and effect of potassium citrate treatment.

Authors:  Antonia Fabris; Patrizia Bernich; Cataldo Abaterusso; Nicola Marchionna; Chiara Canciani; Antonio Nouvenne; Mauro Zamboni; Antonio Lupo; Giovanni Gambaro
Journal:  Clin J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 8.237

4.  Association between Nephrolithiasis, Hypertension and Obesity in Polycystic Kidney Disease.

Authors:  Valbona Bajrami; Alma Idrizi; Enver Roshi; Myftar Barbullushi
Journal:  Open Access Maced J Med Sci       Date:  2015-12-24

5.  Developments in the management of autosomal dominant polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Mir Reza Bekheirnia; Robert W Schrier
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.